| abstract |
The compounds are suitable for the treatment and / or prevention of fatty acid metabolism disorders and glucose utilization disorders as well as disorders in which insulin resistance is involved. Claim 1: A compound of the formula (1), in which: Ring A is cycloalkanediyl (C3-8) or cycloalkennediyl (C3-8) in which one or more carbon atoms of the cycloalkanediyl or cycloalkennediyl rings can be replaced by oxygen atoms; R1, R2 independently of each other are H, F, Br, CF3, OCF3, (C1-6) alkyl-O-(C1-6) alkyl, SCF3, SF5, OCF2-CHF2, O-phenyl, OH, or NO2 ; or R1 and R2 juxtaposed with each other with the phenyl ring are a fused, unsaturated or complete or partially saturated bicyclic-aryl (C9-12) or heteroaryl (C9-11) ring system; R3 is H, CF3, (C1-6) alkyl, (C1-6) alkoxy, (C3-8) cycloalkyl or phenyl; X is C 1-6 alkanediyl, in which one or more carbon atoms in the alkanediyl group can be replaced by oxygen atoms; Y is (C1-6) alkanediyl or (C1-6) alkennediyl, in which one or more CH2 groups in the alkanediyl or alkennediyl group can be replaced by O, CO, S, SO or SO2 and the alkanediyl or alkennediyl can be unsubstituted or substituted by OH; Ring B is phenyl which can be mono- or disubstituted by NO2, Cl, CN, (C1-6) alkyl, (C1-6) alkoxy or tetrazole; or pyrrolidin-2-one which additionally contains a nitrogen or sulfur atom in the ring and which is substituted by oxo or thioxo and can be substituted on the nitrogen atom by R4; R4 is (C1-4) alkyl, phenyl, benzyl; and its physiologically acceptable salts. |